Exane Derivatives Cytokinetics Inc Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
A detailed history of Exane Derivatives transactions in Cytokinetics Inc stock. As of the latest transaction made, Exane Derivatives holds 53 shares of CYTK stock, worth $2,380. This represents 0.0% of its overall portfolio holdings.
Number of Shares
53
Previous 53
-0.0%
Holding current value
$2,380
Previous $1,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CYTK
# of Institutions
397Shares Held
122MCall Options Held
3.46MPut Options Held
1.86M-
Black Rock Inc. New York, NY14.7MShares$659 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.9MShares$535 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.8MShares$483 Million0.31% of portfolio
-
Wellington Management Group LLP Boston, MA7.89MShares$354 Million0.07% of portfolio
-
State Street Corp Boston, MA6.17MShares$277 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $4.23B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...